Company type | GmbH |
---|---|
Industry |
Biotechnology Pharmaceutical |
Founded | 2011 |
Founder | Gerhard Ehninger, Michael Bachmann |
Headquarters | Dresden, Germany |
Key people | Arnim Ehninger, Chief Scientific Officer (CSO), Gerhard Ehninger ( CMO) [1] |
Products | GEM333; GEM3PSCA; UniCAR-T-CD 123, UniCAR-T-PSMA |
Revenue | n.a. |
Website |
www |
GEMoaB is a biopharmaceutical company based in Dresden/ Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann. [2] [3] It was acquired by the new company AvenCell Therapeutics in 2021. [4] [5]
To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies. [6]
The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany). [7]
Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research. [8]
Company type | GmbH |
---|---|
Industry |
Biotechnology Pharmaceutical |
Founded | 2011 |
Founder | Gerhard Ehninger, Michael Bachmann |
Headquarters | Dresden, Germany |
Key people | Arnim Ehninger, Chief Scientific Officer (CSO), Gerhard Ehninger ( CMO) [1] |
Products | GEM333; GEM3PSCA; UniCAR-T-CD 123, UniCAR-T-PSMA |
Revenue | n.a. |
Website |
www |
GEMoaB is a biopharmaceutical company based in Dresden/ Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann. [2] [3] It was acquired by the new company AvenCell Therapeutics in 2021. [4] [5]
To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies. [6]
The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany). [7]
Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research. [8]